Causes, Nature and Toxicology of Fentanyl-Analogues Associated Fatalities: A Systematic Review of Case Reports and Case Series
Umaani Rauf,Majid Ali,Inderpal Dehele,Vibhu Paudyal,Mohamed Hassan Elnaem,Ejaz Cheema
DOI: https://doi.org/10.2147/JPR.S312227
IF: 2.8319
2021-08-24
Journal of Pain Research
Abstract:Umaani Rauf, 1 Majid Ali, 2 Inderpal Dehele, 1 Vibhu Paudyal, 1 Mohamed Hassan Elnaem, 3, 4 Ejaz Cheema 1 1 School of Pharmacy, University of Birmingham, Birmingham, B15 2TT, UK; 2 Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia; 3 Department of Pharmacy Practice, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia; 4 Quality Use of Medicines Research Group, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia Correspondence: Ejaz Cheema School of Pharmacy, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK Tel +44 121-4146845 Email Objective: Mortalities due to fentanyl derivatives are on the rise with novel fentanyl analogues and still emerging on the global illicit drug market. They are highly potent and very fatal in low doses, yet there has been a lack of systematic research surrounding this subject. This review aims to assess the causes, nature, and toxicology of fatalities associated with fentanyl analogues. Methods: Five databases: Scopus, Embase, Medline, PubMed and Google Scholar were searched from inception to October 2020 to identify case studies and case series reporting fentanyl analogue-related fatalities. Two independent reviewers screened and selected the articles followed by the data extraction from each article, which included demography, route of administration, causes and nature of death, and the fentanyl analogue implicated. All articles were then subject to quality assessment tools developed by the Joanna Briggs Institute (JBI). A narrative synthesis was undertaken. Results: The initial data search yielded 834 articles, only 14 of which met the inclusion criteria – this included nine case reports and five case series. Of the 1079 fentanyl-analogue related deaths reported, the majority of them occurred in the US (n=1044, 96.8%). The majority of fatalities were male (n=766, 71%), white (n=884, 87%) and in the age ranges 25– 34 and 35– 44 years (30.5% and 29.6%, respectively). The most common route of administration was intravenous (n=319, 66%) and the manner of death was almost exclusively accidental (99.7%). The predominant cause of death was fentanyl-analogue toxicity (n=292, 85.4%) and involved mixed drug toxicity (n=47, 13.7%). The mean post-mortem fentanyl analogue concentration was 31.6 ng/mL. Conclusion: Most fatalities were reported in the US involving young white males. Overdose through intravenous administration and by mixed drug toxicities with other opioids were the major causes of death. Deaths reported in peer-reviewed literature were relatively less than those reported by real-world data. Keywords: fentanyl-analogues, fatalities, systematic review, case series, case reports Fentanyl and its analogues are synthetic opioid analgesics which act as full agonists for the μ-opioid receptor. 1 Fentanyl itself is 50–100 times more potent than morphine and one of its analogues, carfentanil, is estimated to be 10,000 times more potent. 1 They are of the phenylpiperidine family and were synthesized through modifications of the pethidine (meperidine) structure. 2 Pharmacokinetic properties of fentanyl and its analogues include a highly lipid-soluble structure, that allows for effective and rapid diffusion across the blood–brain barrier, contributing to a rapid onset of effects in the central nervous system. 1 This makes them effective in the management of moderate to severe pain in human and veterinary medicine. However, as with other opioids, possible adverse effects include: respiratory depression, bradycardia, nausea and vomiting, and muscle rigidity of the chest wall or jaw. 3–6 Timely administration of the antidote naloxone can reverse the effects of respiratory depression after the overdose, however, larger and more frequent administrations may be required due to the increased potency of fentanyl analogues compared to other opioids such as heroin. As with opioids such as morphine, codeine and oxycodone, fentanyl and its analogues have the potential for misuse. This could either be in the form of abusing licensed and prescribed fentanyls (such as alfentanil, remifentanil and sufentanil) or the use of illicitly manufactured fentanyls (IMF). Both have been implicated in a large number of fatal overdoses worldwide, but particularly concentrated in the United States (US) where the opioid crisis was declared a nationwide public health emergency in 2017. 7 While the use of the above prescribed fentanyls are restricted to use within hospital and restricted settings, illegal import, manufacturing and di -Abstract Truncated-
clinical neurology